Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Trial ID or NCT#
To investigate if Riociguat is effective in the treatment of systemic sclerosis.
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToAmanda Crawford
Go Back To The Trial